HYKU Biosciences

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

MyCural Therapeutics

This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.

Enlaza Therapeutics

This biotechnology company develops covalent protein medicines that form irreversible bonds with disease targets to treat patients with cancer and autoimmune conditions.

Enlaza

This biotechnology company develops covalent protein medicines using a synthetic biology platform to treat patients with cancer and other serious diseases.

KyDo

This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.

Kymera Therapeutics

This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.

Frontier Medicines

This biopharmaceutical company develops small-molecule precision medicines targeting undruggable proteins for patients with cancer and immunological diseases.

D3 Bio

This biotechnology company develops precision medicines and oncology therapeutics for patients with cancer and immunological conditions.